摘要骨巨细胞瘤(giant tumor of bone，GCTB)约占原发性骨肿瘤的5%~6%，是一种常见的原发性骨肿瘤。20~40岁人群好发，女性发病率略高于男性，最常累及的部位依次是股骨远端、胫骨近端、桡骨远端和骶骨，50%的GCTB出现在膝关节周围，其他常见部位包括腓骨头、股骨近端和肱骨近端，盆腔GCTB是罕见的。尽管大多数GCTB的组织病理学特征是良性的，但某些类型的局部复发率和转移能力仍然很高，大多为肺转移，复发率为2.5%~45%。外科治疗仍然是黄金标准，但术后复发率较高。近年来，许多学者应用聚甲基丙烯酸甲酯(polymethyl methacrylate，PMMA)骨水泥、酒精、过氧化氢等辅助手段对瘤腔进行处理，降低了肿瘤的复发率，但对于特殊部位需要广泛切除及假体重建的患者，仍存在手术难度大、术后并发症多及复发率高的风险。随着现代医学的不断进步，3D打印技术的出现及新兴药物(地诺单抗、双膦酸盐)的应用为其治疗提供了新的选择，但新的治疗策略尚存争议。本文就骨巨细胞瘤的临床治疗进展进行综述。
［1］Palmerini E，Picci P，Reichardt P，et al.Malignancy in giant cell tumor of bone：A review of the literature［J］.Technol Cancer Res Treat，2019(18)：153303381984000.
［2］Sobti A.Giant cell tumor of bone-an overview［J］.Arch Bone Jt Surg，2016，4(1)：2-9.
［3］Li D，Zhang J，Li Y，et al.Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone［J］.World J Surg Oncol，2016，14(1)：114.
［4］Hu X，Lu M，Zhang Y，et al.A biomechanical comparison between cement packing combined with extra fixation and three-dimensional printed strut-type prosthetic reconstruction for giant cell tumor of bone in distal femur［J］.J Orthop Surg Res，2022，17(1)：151.
［5］Tsukamoto S，Mavrogenis AF，Akahane M，et al.Risk factors of fracture following curettage for bone giant cell tumors of the extremities［J］.BMC Musculoskelet Disord，2022，23(1)：477.
［6］Zhou L，Zhu H，Lin S，et al.Computerised tomography features of giant cell tumour of the knee are associated with local recurrence after extended curettage［J］.Int Orthop，2022，46(2)：381-390.
［7］郭卫，李建民，沈靖南，等.骨巨细胞瘤临床循证诊疗指南［J］.中华骨与关节外科杂志，2018，11(4)：276-287.
［8］Omlor GW，Lange J，Streit M，et al.Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone：Local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence［J］.World J Surg Oncol，2019，17(1)：73.
［9］Zheng K，Yu XC，Hu YC，et al.How to fill the cavity after curettage of giant cell tumors around the knee? A multicenter analysis［J］.Chin Med J (Engl)，2017，130(21)：2541-2546.
［10］Tsukamoto S，Mavrogenis AF，Hindiskere S，et al.Outcome of reoperation for local recurrence following en bloc resection for bone giant cell tumor of the extremity［J］.Curr Oncol，2022，29(9)：6383-6399.
［11］Albergo JI，Farfalli GL，Cabas-Geat A，et al.Does osteoarticular allograft reconstruction achieve long-term survivorship after en bloc resection of grade 3 giant cell tumor of bone?［J］.Clin Orthop Relat Res，2020，478(11)：2562-2570.
［12］Lu M，Wang J，Tang F，et al.A three-dimensional printed porous implant combined with bone grafting following curettage of a subchondral giant cell tumour of the proximal tibia：A case report［J］.BMC Surg，2019，19(1)：29.
［13］Luo W，Huang L，Liu H，et al.Customized knee prosthesis in treatment of giant cell tumors of the proximal tibia：Application of 3-Dimensional printing technology in surgical design［J］.Med Sci Monit，2017(23)：1691-1700.
［14］甘锋平，罗翔，陈国平，等.3D打印个性化填充假体治疗膝关节周围骨巨细胞瘤早期疗效［J］.中国修复重建外科杂志，2020，34(6)：751-755.
［15］Wang Y，Min L，Lu M，et al.The functional outcomes and complications of different reconstruction methods for giant cell tumor of the distal radius：Comparison of osteoarticular allograft and three-dimensional-printed prosthesis［J］.BMC Musculoskelet Disord，2020，21(1)：69.
［16］Shibuya I，Takami M，Miyamoto A，et al.In vitro study of the effects of denosumab on giant cell tumor of bone：Comparison with zoledronic acid［J］.Pathol Oncol Res，2019，25(1)：409-419.
［17］Cheng D，Hu T，Zhang H，et al.Factors affecting the recurrence of giant cell tumor of bone after surgery：A clinicopathological study of 80 cases from a single center［J］.Cell Physiol Biochem，2015，36(5)：1961-1970.
［18］Xu R，Choong PFM.Metastatic giant cell tumour of bone：A narrative review of management options and approaches［J］.ANZ J Surg，2022，92(4)：691-696.
［19］Latorre MR，Albergo JI，Farfalli GL，et al.Denosumab as a treatment for giant cell tumor of bone.Indications，results and side effects［J］.Medicina (B Aires)，2021，81(5)：767-773.
［20］虎鑫，文阳，闵理，等.膝关节周围骨巨细胞瘤的外科治疗进展［J］.中华骨与关节外科杂志，2022，15(4)：315-320.
［21］Bukata SV，Blay JY，Rutkowski P，et al.Denosumab treatment for giant cell tumor of the spine including the sacrum［J］.Spine (Phila Pa 1976)，2021，46(5)：277-284.
［22］Hashimoto K，Nishimura S，Miyamoto H，et al.Comprehensive treatment outcomes of giant cell tumor of the spine：A retrospective study［J］.Medicine (Baltimore)，2022，101(32)：E29963.
［23］Fujihara N，Hamada S，Yoshida M，et al.Recurrent giant cell tumour of the distal ulna after en bloc resection with preoperative denosumab use［J］.BMJ Case Rep，2021，14(11)：E245022.
［24］Li H，Gao J，Gao Y，et al.Denosumab in giant cell tumor of bone：Current status and pitfalls［J］.Front Oncol，2020(10)：580605.
［25］Basu Mallick A，Chawla SP.Giant cell tumor of bone：An update［J］.Curr Oncol Rep，2021，23(5)：51.
［26］Alaqaili SI，Abduljabbar AM，Altaho AJ，et al.Malignant sarcomatous transformation of benign giant cell tumor of bone after treatment with denosumab therapy：A literature review of reported cases［J］.Cureus，2018，10(12)：E3792.
［27］Lau HW，Wong KC，Chiu WK，et al.Local recurrence after minimally invasive curettage for primary giant cell tumor of bone with perioperative bisphosphonate is comparable to open curettage：Retrospective comparison with 9-year follow-up［J］.Arthrosc Sports Med Rehabil，2021，3(6)：e1729-e1736.
［28］Kanwat H，Banjara R，Kumar VS，et al.Comparison of denosumab and zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone［J］.J Orthop Surg (Hong Kong)，2021，29(2)：230949902110075.
［29］Dubey S，Rastogi S，Sampath V，et al.Role of intravenous zoledronic acid in management of giant cell tumor of bone-A prospective，randomized，clinical，radiological and electron microscopic analysis［J］.J Clin Orthop Trauma，2019，10(6)：1021-1026.
［30］Tse LF，Wong KC，Kumta SM，et al.Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone：A case-control study［J］.Bone，2008，42(1)：68-73.
［31］Yu X，Xu M，Xu S，et al.Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation，and oral bisphosphonates［J］.Oncol Lett，2013，5(2)：447-451.
［32］Martin C，McCarthy EF.Giant cell tumor of the sacrum and spine：Series of 23 cases and a review of the literature［J］.Iowa Orthop J，2010(30)：69-75.
［33］Yu X，Xu M，Xu S，et al.Long-term outcome of giant cell tumor of bone involving sacroiliac joint treated with selective arterial embolization and curettage：A case report and literature review［J］.World J Surg Oncol，2013，11(1)：72.
［34］Onishi H，Kaya M，Wada T，et al.Giant cell tumor of the sacrum treated with selective arterial embolization［J］.Int J Clin Oncol，2010，15(4)：416-419.
［35］Balke M，Henrichs MP，Gosheger G，et al.Giant cell tumors of the axial skeleton［J］.Sarcoma，2012(2012)：1-10.
［36］Kriz J，Eich HT，Mücke R，et al.Radiotherapy for giant cell tumors of the bone：A safe and effective treatment modality［J］.Anticancer Res，2012，32(5)：2069-2073.
［37］Ma Y，Xu W，Yin H，et al.Therapeutic radiotherapy for giant cell tumor of the spine：A systemic review［J］.Eur Spine J，2015，24(8)：1754-1760.
［38］Shi W，Indelicato DJ，Reith J，et al.Radiotherapy in the management of giant cell tumor of bone［J］.Am J Clin Oncol，2013，36(5)：505-508.
［39］Lin JL，Wu YH，Shi YF，et al.Survival and prognosis in malignant giant cell tumor of bone：A population-based analysis from 1984 to 2013［J］.J Bone Oncol，2019(19)：100260.
［40］Caudell JJ，Ballo MT，Zagars GK，et al.Radiotherapy in the management of giant cell tumor of bone［J］.Am J Clin Oncol，2003，57(1)：158-165.
晋公网安备 14010702070875号